Poolbeg Pharma a year of substantial progress

Poolbeg Pharma

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting 2022 have been posted to shareholders.

The Notice of AGM and accompanying form of proxy are available to download from the Company’s website: https://www.poolbegpharma.com/investors/documents/  while the 2022 Annual Report and Accounts can be viewed and downloaded below.

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 11 May 2023 at 12pm.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy.

Poolbeg Pharma CEO participating in key conferences in March and April 2025

Poolbeg Pharma's CEO, Jeremy Skillington, will present at major industry conferences in March and April 2025, showcasing innovative therapies and advancements.

Poolbeg Pharma granted patent in Korea for POLB 001

Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions.

Poolbeg Pharma granted extension to PUSU Deadline

HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs.

Search

Search